ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GH vs LH // EV/EBITDA & P/E VALUATION

Guardant Health Inc. (NASDAQ) VS. Labcorp Holdings Inc. (NYSE) • 15-METRIC TALLY: GH 4 — LH 9
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GH VS. LH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GH LH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 64.50% 28.80% +35.70 GH /gross-margins <GO>
Return on Invested Capital (ROIC) -17.40% 8.30% -25.70 LH /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 19.6x — TIE /valuation <GO>
Free Cash Flow Yield -0.94% 4.04% -4.98 LH /fcf-yield <GO>
Operating Margin -44.50% 9.90% -54.40 LH /operating-margins <GO>
Net Profit Margin -42.40% 6.30% -48.70 LH /net-margins <GO>
Revenue Growth (YoY) 32.90% 7.20% +25.70 GH /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.81% -0.81 LH /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.44 3.58 +1.86 GH /balance-sheet <GO>
Piotroski F-Score Quality 6/9 8/9 -2.00 LH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 62.0 76.9 -14.90 LH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.87 0.96 -0.09 LH /macro-sensitivity <GO>
Forward P/E Multiple 19.0x 31.6x -12.60 GH /forward-pe <GO>
Enterprise Scale & Market Cap $24.87B $29.86B -$4.99B LH /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GH REV LH REV GH GROSS % LH GROSS % GH FCF LH FCF
FY 2025 $982.0M $13.95B 64.5% 28.8% -$233.1M $1.21B
FY 2024 $739.0M $13.01B 60.8% 27.9% -$274.9M $1.10B
FY 2023 $563.9M $12.16B — — -$350.4M $780.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GH // BETA 0.87
LH // BETA 0.96